Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Bachy

Showing results (161-170 of 176) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP TrialVincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
Journal of Hematology & Oncology|October 29, 2024
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatmentGloria Iacoboni, Víctor Navarro, Pierre Sesques, et al.
Blood|June 10, 2023
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendationsKai Rejeski, Marion Subklewe, Mahmoud Aljurf, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation GroupDiana Averbuch, Gloria Tridello, Jennifer Hoek, et al.
Journal of Hematology & Oncology|August 6, 2024
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphomaPierre Sesques, Amy A Kirkwood, Mi Kwon, et al.
Nature Medicine|December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.
Hemasphere|January 22, 2025
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSAAmira Marouf, Sammara Chaubard, Raphaël Liévin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular LymphomaFranck Morschhauser, Loretta Nastoupil, Pierre Feugier, et al.
Blood Advances|August 4, 2025
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II StudyOlivier Tournilhac, Krimo Bouabdallah, Solene Lecolant, et al.
Nature|June 22, 2018
A multiprotein supercomplex controlling oncogenic signalling in lymphomaJames D Phelan, Ryan M Young, Daniel E Webster, et al.
Pageof 18

Showing results (161-170 of 176) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP TrialVincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
Journal of Hematology & Oncology|October 29, 2024
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatmentGloria Iacoboni, Víctor Navarro, Pierre Sesques, et al.
Blood|June 10, 2023
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendationsKai Rejeski, Marion Subklewe, Mahmoud Aljurf, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation GroupDiana Averbuch, Gloria Tridello, Jennifer Hoek, et al.
Journal of Hematology & Oncology|August 6, 2024
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphomaPierre Sesques, Amy A Kirkwood, Mi Kwon, et al.
Nature Medicine|December 18, 2021
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNathan Hale Fowler, Michael Dickinson, Martin Dreyling, et al.
Hemasphere|January 22, 2025
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSAAmira Marouf, Sammara Chaubard, Raphaël Liévin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2022
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R<sup>2</sup>) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular LymphomaFranck Morschhauser, Loretta Nastoupil, Pierre Feugier, et al.
Blood Advances|August 4, 2025
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II StudyOlivier Tournilhac, Krimo Bouabdallah, Solene Lecolant, et al.
Nature|June 22, 2018
A multiprotein supercomplex controlling oncogenic signalling in lymphomaJames D Phelan, Ryan M Young, Daniel E Webster, et al.
Pageof 18